These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Bomback AS; Toto R Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925 [TBL] [Abstract][Full Text] [Related]
6. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325 [TBL] [Abstract][Full Text] [Related]
7. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
8. The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Norris K; Vaughn C Expert Rev Cardiovasc Ther; 2003 May; 1(1):51-63. PubMed ID: 15030297 [TBL] [Abstract][Full Text] [Related]
9. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458 [TBL] [Abstract][Full Text] [Related]
10. Managing hypertension using combination therapy. Frank J Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493 [TBL] [Abstract][Full Text] [Related]
11. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Shavit L; Lifschitz MD; Epstein M Kidney Int; 2012 May; 81(10):955-968. PubMed ID: 22336987 [TBL] [Abstract][Full Text] [Related]
12. Facility variation in utilization of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and chronic kidney disease. Tiwari A; Tseng CL; Kern EF; Maney M; Miller DR; Pogach L Am J Manag Care; 2007 Feb; 13(2):73-9. PubMed ID: 17286527 [TBL] [Abstract][Full Text] [Related]
13. Extracellular volume and aldosterone interaction in chronic kidney disease. Klemmer PJ; Bomback AS Blood Purif; 2009; 27(1):92-8. PubMed ID: 19169025 [TBL] [Abstract][Full Text] [Related]
17. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Weir MR; Rolfe M Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448 [TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. Turgut F; Balogun RA; Abdel-Rahman EM Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247 [TBL] [Abstract][Full Text] [Related]
19. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Agarwal R Am J Physiol Renal Physiol; 2003 Apr; 284(4):F863-9. PubMed ID: 12505865 [TBL] [Abstract][Full Text] [Related]
20. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Schrier RW; Masoumi A; Elhassan E Clin J Am Soc Nephrol; 2010 Jun; 5(6):1132-40. PubMed ID: 20448074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]